HUAWEI
26.3.2019 17:06:04 CET | Business Wire | Press release
During an exclusive launch event today at the Paris Convention Center, Huawei Consumer Business Group (BG) unveiled the HUAWEI P30 and HUAWEI P30 Pro. The HUAWEI P30 Series builds on the HUAWEI P Series DNA in design and photography and is the company’s most advanced series of smartphone cameras. These devices feature the innovative HUAWEI SuperSpectrum Sensor, an optical SuperZoom Lens, a new HUAWEI Time of Flight (ToF) Camera, and enhanced optical and AI image stabilization technology. With these revolutionary technologies, the HUAWEI P30 and HUAWEI P30 Pro capture incredible photos and videos in every scenario.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005752/en/
Richard Yu, CEO of Huawei Consumer BG, said, “the HUAWEI P30 Series is a fundamental breakthrough after decades of digital camera technology development; it will rewrite the rules and reshape everyone’s perception of mobile photography. Innovations such as the HUAWEI SuperSpectrum Sensor and SuperZoom Lens allow us to push the envelope of both photography and videography—a frontier long overdue for disruption. The HUAWEI P30 Series will set the pace for the next generation of smartphones by empowering people to capture the true beauty of the world around them through a device that fits in the palm of their hands.”
Rewriting the Rules of Photography for Stunning Professional-grade Pictures Every Time
Achieving a record-high overall DxOMark score of 112, the HUAWEI P30 Pro is equipped with a new Leica Quad Camera System, including a 40MP main camera with the HUAWEI SuperSpectrum Sensor, a 20MP ultra-wide angle camera, an 8MP telephoto camera, the HUAWEI ToF Camera and a 32MP front camera that takes selfies to a new level.
The 1/1.7-inch HUAWEI SuperSpectrum Sensor looks at light in a fundamentally new way. The RYYB HUAWEI SuperSpectrum Sensor deviates from the traditional RGGB Bayer filter by replacing green pixels with yellow pixels, yielding a high maximum ISO rating of 409,600 on the HUAWEI P30 Pro and 204,800 on the HUAWEI P30. This fundamental shift in sensor technology, combined with HUAWEI AIS, OIS and the HUAWEI P30 Pro’s f/1.6 wide aperture, delivers extraordinary photography and videography experiences across a wide range of scenarios and lighting conditions—including extreme low light—producing images with enhanced detail, color and clarity.
Through a new periscope design, the SuperZoom Lens supports high fidelity magnification of 5 times optical zoom, 10 times hybrid zoom and 50 times digital zoom. A prism element in the telephoto camera bends light at a 90-degree angle to maximize focal length while minimizing camera height, without disrupting device design.
Unique to the HUAWEI P30 Pro is a HUAWEI ToF Camera that captures depth-of-field information to deliver accurate image segmentation. Precise distance measurement allows for the simulation of multiple levels of bokeh. The Super Portrait feature captures even the smallest details, such as individual strands of hair. It combines depth information and proprietary algorithms to produce outstanding images with defocused backgrounds and highlights the subject of the image in any scenario.
Redefining Smartphone Videography
The HUAWEI SuperSpectrum Sensor enables spectacular low-light video capture so night scenes appear bright and highly detailed. HUAWEI AIS and OIS support stabilization for all video capture settings, resulting in a perfect, steady shot. Additionally, the SuperZoom Lens allows for crisp close-ups, while the AI Video Editor enables users to add background music and special effects to their videos, turning the HUAWEI P30 Series into a mobile production studio.
A Heritage of Stunning Design
The HUAWEI P30 Series design, created with a nine-layer nano optical color finish, is inspired by the unique color palette and pristine look of salt flats. The 6.47-inch HUAWEI P30 Pro and 6.1-inch HUAWEI P30 come in Breathing Crystal, Amber Sunrise, Aurora, Pearl White and Black. The FHD+ (2340x1080) Dewdrop Display features a tiny notch, providing maximum display area. The near bezel-less front glass houses an In-Screen Fingerprint sensor for quick and secure identity authentication. The HUAWEI P30 Pro also features HUAWEI Acoustic Display Technology that enables it to deliver high-quality audio through a sound emitting display.
Ultimate Innovation
The HUAWEI P30 and HUAWEI P30 Pro are packed with industry-leading features that set them apart in power, performance and efficiency:
- The HUAWEI P30 Series is powered by the 7nm Kirin 980 processor, which delivers ultimate performance, top-class efficiency and faster image recognition through its Dual-NPU AI processing power.
- The HUAWEI P30 Series features an Extendable Read-Only File System that improves system responsiveness. The latest EMUI 9.1 also supports HUAWEI Share OneHop for seamless file sharing between Huawei smartphones and Huawei laptops.
- The HUAWEI P30 Pro features a 4200mAh battery (typical value) and 40W HUAWEI SuperCharge that charges a device from zero to 70 percent in 30 minutes, keeping the device powered for more than a full day of intensive work.
- The HUAWEI P30 Pro features HUAWEI SuperCool technology to improve thermal performance, keeping the phone cool even during heavy use.
- The HUAWEI P30 Series is equipped with a suite of advanced wireless communications capabilities supporting Dual SIM and Dual VoLTE connectivity1 .
Pricing and Availability
Starting at EUR 799 and EUR 999 respectively, the new HUAWEI P30 and HUAWEI P30 Pro are immediately available globally.
About Huawei Consumer BG
Huawei’s products and services are
available in more than 170 countries and are used by a third of the
world’s population. Fifteen R&D centers have been set up in the United
States, Germany, Sweden, Russia, India and China. Huawei Consumer BG is
one of Huawei’s three business units and covers smartphones, PC and
tablets, wearables and cloud services, etc. Huawei’s global network is
built on almost 30 years of expertise in the telecom industry and is
dedicated to delivering the latest technological advances to consumers
around the world.
1 Specific features may vary depending on regional availability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190326005752/en/
Contact:
Mark Fowler +44 (0)208 811 2474 Huawei@racepointglobal.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom